Favorable-Risk RCC: Frontline VEGF TKI/IO Combinations

Frontline RCC Treatment Selection: IO/IO Versus IO/TKIПодробнее

Favorable-Risk RCC: Options for VEGF TKI MonotherapyПодробнее

Dr Tan on the Efficacy and Safety of IO-IO and IO-TKI Combination Regimens in RCCПодробнее

VEGF TKI Therapy in the Adjuvant Setting of RCCПодробнее

Patient Selection for IO/IO Versus IO/TKI in the Frontline SettingПодробнее

VEGF-TKI Therapy in First-Line mRCCПодробнее

A Novel Approach: TKI/I-O Combinations in RCCПодробнее

Understanding and Working With New Immunotherapeutic and Targeted Management Models in Advanced RCCПодробнее

Balancing Risks and Rewards in RCC: IO Combinations for Different Patient ProfilesПодробнее

Choosing an IO/TKI Doublet for RCC Patients: Efficacy Data, Dosing, and MoreПодробнее

Dr. Figlin on Toxicity Profile of Immunotherapy/VEGF TKI Combinations in RCCПодробнее

TKI/IO Comparison: Lenvatinib/Pembrolizumab vs Cabozantinib/Nivolumab vs Axitinib/PembrolizumabПодробнее

The Latest Data on IO/TKI Versus IO/IO in Frontline RCCПодробнее

mRCC: When is TKI/I-O Combination Therapy Appropriate?Подробнее

Immunotherapy Combinations Improve Survival in Advanced Renal Cell CarcinomaПодробнее

#UromigosLive24 RCC IO Rechallenge Panel Part 4: What About CTLA-4-Based Salvage After IO in RCC?Подробнее

Favorable-Risk RCC: Factors in Selecting TherapyПодробнее

Selecting Immunotherapy versus VEGF TKI for mRCCПодробнее

The Uromigos: Frontline Therapy in RCCПодробнее